An Open-Label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics of BRI-1501 Tablet and Coadministration of Lafutidine and Irsogladine maleate as Individual Tablets in Healthy Adult Volunteers

Inclusion Criteria:

• Healthy subject, aged 19- 50 years

Exclusion Criteria:

• History of clinically significant and active disease
• History of gastrointestinal disease
• History of clinically significant hypersensitivity to study drug, any other drug
• Laboratory test serum AST or ALT > 1.25 times of upper normal range serum total bilirubin > 1.5 times of upper normal range eGFR < 60 ml/min/1.73m² serological test(HBsAg, HCV Ab, HIV Ag/Ab, Syphilis reagin) positive
• Hypotension or hypertension
• Pregnant or nursing women
• Participation in any other study within 90 days